Instructions,
not fuel.

Selection is made by your physician at assessment, from what is currently permissible and appropriate for your clinical picture. Valere does not publish a fixed list, and the reason is regulatory rather than evasive: the landscape for individual compounds in this category is active and changes. A practice advertising a static menu of peptide names is either not tracking those changes or has decided not to care about them. What we will tell you, at assessment and in writing, is exactly what is being prescribed to you and why.

Some peptide drugs are FDA-approved for specific indications. The protocols used in an optimization context are off-label applications, meaning a physician is applying clinical judgment outside the labelled indication — which is legal, common across medicine, and different from something being unapproved or unregulated. What matters is that the prescribing is done by a licensed physician against an individual prescription, and that the preparation comes from a legitimate 503A compounding pharmacy. Both are true here. Nothing on this page should be read as a claim that these treat any disease.

Supplying growth hormone directly delivers a flat external level and suppresses the body's own production over time. A secretagogue instead prompts your pituitary to release its own, in the pulsatile rhythm it normally uses, still subject to its own negative feedback — which is why the literature notes it can avoid the supra-therapeutic levels that direct administration risks. That review is at PubMed. It is a meaningfully different approach, though it is not a free lunch and your physician will cover the trade-offs.

For growth hormone secretagogues specifically, published review reports improvements in lean mass and fat-free mass, effects on sleep, and a generally tolerable safety profile — with attention warranted on blood glucose and insulin sensitivity. The same review states directly that few long-term, rigorously controlled studies exist and that more work is needed on long-term impact including cancer incidence and mortality. That is the honest state of it. Your physician will tell you where a proposed protocol sits against that evidence rather than overstating it.

A 503B outsourcing facility produces batches to one fixed specification without patient-specific prescriptions. A 503A pharmacy compounds against a prescription written for one named patient, at the dose that patient's physician specified. Both are legitimate regulatory pathways, defined by the FDA — but only one of them can adapt to your panel and be adjusted as your follow-up bloodwork indicates. Since the entire model here is individualized prescribing, 503A is the only route that makes sense.

Peptide protocols are typically run in defined cycles rather than continuously, with follow-up panels at six to eight weeks determining whether to continue, adjust, or stop. Some are used for a specific window — preparing for cellular work, or through a period of concentrated recovery — and then discontinued. Others run longer where the panel supports it. What is not appropriate is an indefinite protocol nobody is monitoring, which is why the follow-up is built in rather than optional.

No. Valere operates as a private-pay practice, and compounded peptide protocols are not covered by standard insurance. That is what allows the protocol to be built around your panel rather than around what is reimbursable, and what makes the 503A route and the follow-up monitoring possible. Payment plans and membership options are available, and cost is discussed after your panel is reviewed rather than quoted from a list.